- Home
- OCEA vs TENX Comparison
OCEA vs TENX Comparison
Compare OCEA & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEA
- TENX
- Stock Information
- Founded
- OCEA 2019
- TENX 1967
- Country
- OCEA United States
- TENX United States
- Employees
- OCEA N/A
- TENX N/A
- Industry
- OCEA Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- OCEA Health Care
- TENX Health Care
- Exchange
- OCEA Nasdaq
- TENX Nasdaq
- Market Cap
- OCEA 20.5M
- TENX 21.8M
- IPO Year
- OCEA N/A
- TENX N/A
- Fundamental
- Price
- OCEA $0.54
- TENX $6.37
- Analyst Decision
- OCEA
- TENX Strong Buy
- Analyst Count
- OCEA 0
- TENX 4
- Target Price
- OCEA N/A
- TENX $20.67
- AVG Volume (30 Days)
- OCEA 617.7K
- TENX 38.7K
- Earning Date
- OCEA 01-13-2025
- TENX 11-13-2024
- Dividend Yield
- OCEA N/A
- TENX N/A
- EPS Growth
- OCEA N/A
- TENX N/A
- EPS
- OCEA N/A
- TENX N/A
- Revenue
- OCEA N/A
- TENX N/A
- Revenue This Year
- OCEA N/A
- TENX N/A
- Revenue Next Year
- OCEA N/A
- TENX N/A
- P/E Ratio
- OCEA N/A
- TENX N/A
- Revenue Growth
- OCEA N/A
- TENX N/A
- 52 Week Low
- OCEA $0.46
- TENX $2.77
- 52 Week High
- OCEA $7.79
- TENX $21.46
- Technical
- Relative Strength Index (RSI)
- OCEA 40.01
- TENX 57.59
- Support Level
- OCEA $0.53
- TENX $5.92
- Resistance Level
- OCEA $0.70
- TENX $6.65
- Average True Range (ATR)
- OCEA 0.08
- TENX 0.43
- MACD
- OCEA -0.00
- TENX -0.02
- Stochastic Oscillator
- OCEA 4.31
- TENX 56.21
About OCEA Ocean Biomedical Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.